CL2022003435A1 - Métodos de tratamiento del complejo de esclerosis tuberosa - Google Patents
Métodos de tratamiento del complejo de esclerosis tuberosaInfo
- Publication number
- CL2022003435A1 CL2022003435A1 CL2022003435A CL2022003435A CL2022003435A1 CL 2022003435 A1 CL2022003435 A1 CL 2022003435A1 CL 2022003435 A CL2022003435 A CL 2022003435A CL 2022003435 A CL2022003435 A CL 2022003435A CL 2022003435 A1 CL2022003435 A1 CL 2022003435A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- tuberous sclerosis
- treatment
- sclerosis complex
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Preparation Of Fruits And Vegetables (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035313P | 2020-06-05 | 2020-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003435A1 true CL2022003435A1 (es) | 2023-10-20 |
Family
ID=76325558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003435A CL2022003435A1 (es) | 2020-06-05 | 2022-12-05 | Métodos de tratamiento del complejo de esclerosis tuberosa |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11684613B2 (enExample) |
| EP (1) | EP4161512A1 (enExample) |
| JP (2) | JP2023528895A (enExample) |
| KR (2) | KR20230027145A (enExample) |
| CN (1) | CN116056701A (enExample) |
| AU (1) | AU2021285273A1 (enExample) |
| BR (1) | BR112022024760A2 (enExample) |
| CA (1) | CA3180794A1 (enExample) |
| CL (1) | CL2022003435A1 (enExample) |
| IL (2) | IL322310A (enExample) |
| MX (1) | MX2022015407A (enExample) |
| PH (1) | PH12023550016A1 (enExample) |
| WO (1) | WO2021245281A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022015407A (es) * | 2020-06-05 | 2023-05-16 | Noema Pharma Ag | Metodos de tratamiento del complejo de esclerosis tuberosa. |
| CN120641098A (zh) * | 2023-02-02 | 2025-09-12 | 诺埃玛制药公司 | Dravet综合征的治疗方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4508560A (en) | 1981-11-11 | 1985-04-02 | Ciba Geigy Corporation | Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use |
| CN100548299C (zh) | 2001-01-05 | 2009-10-14 | 伊莱利利公司 | 兴奋性氨基酸受体拮抗剂 |
| TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| HRP20080363T3 (hr) | 2004-06-01 | 2008-09-30 | F. Hoffmann - La Roche Ag | Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora |
| EP1756086B1 (en) | 2004-06-01 | 2008-06-04 | F.Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists |
| AU2007336369B2 (en) * | 2006-12-21 | 2013-01-17 | F. Hoffmann-La Roche Ag | Polymorphs of a mGluR5 receptor antagonist |
| US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| JP2013505262A (ja) | 2009-09-17 | 2013-02-14 | バンダービルト ユニバーシティー | mGluR5ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法 |
| US20120039999A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| CA2845578C (en) | 2011-08-25 | 2016-02-16 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| MX2022015407A (es) * | 2020-06-05 | 2023-05-16 | Noema Pharma Ag | Metodos de tratamiento del complejo de esclerosis tuberosa. |
| TWI924682B (zh) | 2020-07-30 | 2026-05-11 | 瑞士商諾埃瑪製藥公司 | 三叉神經痛之治療方法 |
| US20240285637A1 (en) | 2021-07-08 | 2024-08-29 | The Royal Institution For The Advancement Of Learning/Mcgill University | Phosphodiesterase inhibitors for the mitigation of fragile x syndrome symptoms |
| CN119677515A (zh) | 2022-06-15 | 2025-03-21 | 美国政府健康及人类服务部 | 使用代谢型谷氨酸受体5拮抗剂或/和大麻素受体1拮抗剂治疗纤维化疾病 |
| EP4584250A4 (en) | 2022-09-06 | 2026-02-25 | Biohaven Therapeutics Ltd | POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS |
| US20260124188A1 (en) | 2022-10-28 | 2026-05-07 | Orphelion Ab | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal |
| CN120641098A (zh) | 2023-02-02 | 2025-09-12 | 诺埃玛制药公司 | Dravet综合征的治疗方法 |
| EP4680203A1 (en) | 2023-03-14 | 2026-01-21 | Prolevi Bio AB | Compositions for sustained release of poorly soluble active ingredients |
-
2021
- 2021-06-04 MX MX2022015407A patent/MX2022015407A/es unknown
- 2021-06-04 BR BR112022024760A patent/BR112022024760A2/pt unknown
- 2021-06-04 KR KR1020237000370A patent/KR20230027145A/ko not_active Ceased
- 2021-06-04 CN CN202180057592.9A patent/CN116056701A/zh active Pending
- 2021-06-04 CA CA3180794A patent/CA3180794A1/en active Pending
- 2021-06-04 KR KR1020257024877A patent/KR20250116184A/ko active Pending
- 2021-06-04 JP JP2022574675A patent/JP2023528895A/ja active Pending
- 2021-06-04 IL IL322310A patent/IL322310A/en unknown
- 2021-06-04 WO PCT/EP2021/065075 patent/WO2021245281A1/en not_active Ceased
- 2021-06-04 PH PH1/2023/550016A patent/PH12023550016A1/en unknown
- 2021-06-04 EP EP21730918.6A patent/EP4161512A1/en active Pending
- 2021-06-04 AU AU2021285273A patent/AU2021285273A1/en active Pending
- 2021-06-04 IL IL298709A patent/IL298709A/en unknown
-
2022
- 2022-12-02 US US18/061,239 patent/US11684613B2/en active Active
- 2022-12-05 CL CL2022003435A patent/CL2022003435A1/es unknown
-
2023
- 2023-05-11 US US18/315,723 patent/US11998535B2/en active Active
-
2024
- 2024-04-22 US US18/641,640 patent/US12702661B2/en active Active
-
2025
- 2025-05-19 JP JP2025082998A patent/JP2025122066A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL322310A (en) | 2025-09-01 |
| US12702661B2 (en) | 2026-08-11 |
| PH12023550016A1 (en) | 2024-03-11 |
| KR20250116184A (ko) | 2025-07-31 |
| US20230100520A1 (en) | 2023-03-30 |
| US11998535B2 (en) | 2024-06-04 |
| IL298709A (en) | 2023-02-01 |
| JP2023528895A (ja) | 2023-07-06 |
| JP2025122066A (ja) | 2025-08-20 |
| BR112022024760A2 (pt) | 2023-03-07 |
| WO2021245281A1 (en) | 2021-12-09 |
| MX2022015407A (es) | 2023-05-16 |
| US20230277513A1 (en) | 2023-09-07 |
| EP4161512A1 (en) | 2023-04-12 |
| CN116056701A (zh) | 2023-05-02 |
| CA3180794A1 (en) | 2021-12-09 |
| AU2021285273A1 (en) | 2023-01-19 |
| KR20230027145A (ko) | 2023-02-27 |
| US20250099445A1 (en) | 2025-03-27 |
| US11684613B2 (en) | 2023-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004858A (es) | Compuestos moduladores de sting y metodos de elaboracion y uso. | |
| AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
| CL2019002220A1 (es) | Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos. | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| CO2023013321A2 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| BR112022012130A2 (pt) | Compostos antelmínticos compreendendo uma estrutura azaindólica | |
| MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
| CL2024002623A1 (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2. | |
| CO2024003723A2 (es) | Compuestos de imidazopiridazina inhibidores de il-17 | |
| CU24550B1 (es) | Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos | |
| NI202100055A (es) | Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéutica del mismo. | |
| MX2020004842A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| BR112022003659A2 (pt) | Composições e métodos de tratamento de doenças vasculares | |
| BR112022020451A2 (pt) | Composição de fragrância | |
| DOP2025000212A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2024010671A (es) | Compuestos antivirales y metodos de elaboracion y uso de los mismos. | |
| MX2024008333A (es) | Compuestos para tratamiento de pérdida de cabello. | |
| BR112022005736A2 (pt) | Compostos de azaindol carboxamida para o tratamento de infecções micobacterianas | |
| UY38304A (es) | Dinucleótidos cíclicos como agonistas de sting y composiciones farmacéuticas que los contienen | |
| MX392365B (es) | Conversion mejorada de taurina a amida de alquiltaurato utilizando catalizadores de acido fosforico | |
| PH12023550016A1 (en) | Methods of treatment of tuberous sclerosis complex | |
| MX2024007064A (es) | Metodos de administracion de un modulador de hemoglobina. | |
| CL2023000261A1 (es) | Métodos de tratamiento de la neuralgia del trigémino | |
| RU2014123690A (ru) | Терапевтическое средство при артрозе | |
| CO2025001506A2 (es) | Formas sólidas de un derivado de triazina como modulador cbl-b |